We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Saturday
May 16
15:15 - 16:15
Poster Area
Lung cancer
Poster Highlights
Clinical
Predicting eligibility for adjuvant immunotherapy following chemoradiotherapy in stage III non-small-cell lung cancer
Arno Hessels, The Netherlands
-61
A 22-gene idiopathic pulmonary fibrosis–associated signature predicts overall survival in non-small cell lung cancer
Ahmed Salem, Jordan
-936
Cardiac Toxicity in Patients with Central and Ultracentral Lung Tumors Treated with SBRT: A Multicentric Study
Axel Licha, France
-1044
Survival outcomes after carbon-ion–based radiotherapy for tracheobronchial adenoid cystic carcinoma
Stella Winter, Germany
-1223
A Prospective Study of Surveillance Imaging with Multiparametric MRI and PET-CT in Lung Patients Post-Stereotactic Ablative Radiotherapy (SIMPLE-AS)
Shalini Vinod, Australia
-1688
Dose-escalated stereotactic MR-guided adaptive RT for ultracentral lung tumors: First-year cardiopulmonary data of the prospective MAGELLAN trial
Markus Ehle, Germany
-1831
34Gy single fraction vs 54Gy in 3 fraction stereotactic radiotherapy for early-stage NSCLC: a two-centre experience and propensity matched analysis
Sumeet Hindocha, United Kingdom
-1880
Outcomes following radiotherapy for patients with locally advanced non-small cell lung cancer and interstitial lung disease – a systematic review
George Li, Canada
-2293
Primer-shot radiotherapy for NSCLC: a prospective feasibility trial (NCT06528743)
Zeno Gouw, The Netherlands
-2342
Can Radiation Dose to the Sinoatrial and Atrioventricular Nodes Predicts Atrial Fibrillation?
Ilayda Yalman, Turkey
-2491
Target Trial Emulation of Dose to a Novel Cardiac Avoidance and Cardiac Related Mortality in Lung Radiotherapy
Azadeh Abravan, United Kingdom
-2500
Prognostic value of longitudinal nutritional and inflammatory scores in NSCLC patients undergoing radiotherapy: a prospective study (UMIN000056183)
Zhe Chen, Japan
-99
Impact of heart-base dose limit implementation on oesophagitis and pneumonitis in lung cancer radiotherapy: RAPID-RT study
Catharine Morgan, United Kingdom
-2859
Stereotactic ablative radiotherapy (SABR) versus surgical resection for early-stage non-small lung cancer (NSCLC): The SORT study
Eva Kagenaar, United Kingdom
-2955
Progression patterns in patients with synchronous oligometastatic NSCLC after systemic and LRT: results from a multicentric retrospective study
Valentina Bartolomeo, Italy
-3076
Efficacy and safety of radical thoracic re-irradiation in patients with lung malignancies
Federico Colombo, Italy
-3517
Impact of prescription method on local control and side effects of stereotactic radiotherapy for pulmonary oligometastases
Davide Franceschini, Italy
-3761
Patient selection improves prediction of tumour volume regression in NSCLC, in a single parameter, Proliferation Saturation Index mathematical model
Sarah Barrett, Ireland
-4054
Is the Internal Target Volume important to control subclinical disease during Stereotactic Ablative Radiotherapy for lung cancer?
Marcel van Herk, United Kingdom
-4167
Quantitative imaging and dosimetric signatures define survival clusters and inform dose optimisation in locally advanced NSCLC
Alessandro Cicchetti, Italy
-4295
Longitudinal imaging analysis of bone and lung oligometastases after SBRT and immunochemotherapy: a secondary analysis of the ETOP CHESS trial
Nicolas MARTZ, France
-4352
Outcomes of intensity-modulated proton therapy in unresectable stage III NSCLC treated with chemoradiotherapy in the durvalumab era
Kyra van Keeken, The Netherlands
-4372
Radiotherapy (RT) for Ultracentral Lung Tumors: Balancing Tumor Control and Side Effects
Laura Guzmán Gómez, Spain
-102
Impact of combined ILD and lung cancer multidisciplinary team assessment on treatment selection and toxicity.
Mathijs Tomassen, The Netherlands
-4382
Time to treatment with stereotactic body radiation therapy and overall survival for non-small cell lung cancer
Cassidy Laub, Canada
-4492
Twelve-month radiographic disease control by Green criteria independently predicts survival after hypofractionated radiotherapy for NSCLC
Hebatalla Abdelaal, United Kingdom
-4578
Early dosimetric and adaptive experience from the first patients on the UK HIT-Meso (NCT05655078) clinical trial
Andrew GOSLING, United Kingdom
-4601
Cardiac Adverse Events Following Post-Operative Radiation Therapy in Patients with Thymomas
Oded Icht, Israel
-324
The effect of adjuvant radiation after thymectomy for thymoma patients on the risk of myasthenia gravis exacerbation (MGe)
Sarit Appel, Israel
-640
Exploring Survival Heterogeneity in Randomised Trials of Stereotactic Ablative Radiotherapy (RT) vs Conventional RT in Early Stage NSCLC
Zhi Xuan Ng, Singapore
-657
Identifying cardiac risk profiles to personalize chemoradiotherapy in thoracic cancer
Arno Hessels, The Netherlands
-686
Durvalumab improves progression-free survival and sequential radiotherapy improves locoregional and local control in elderly NSCLC Stage III patients
Brane Grambozov, Austria
-699
Impact of adding metastatic ablative radiotherapy to Lung Consolidation in Oligometastatic NSCLC: A Randomized Controlled Study
Brahma Prasad Sadangi, India
-757